커넥티드 약물전달 디바이스 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Connected Drug Delivery Devices Market was valued at USD 491.2 million in 2024 and is anticipated to expand at a robust CAGR of 31.8% from 2025 to 2034. These devices integrate modern technology, such as Bluetooth, Wi-Fi, and the Internet of Things (IoT), to improve medication management and administration. They include smart inhalers, insulin pens, wearable injectors, and intelligent pill dispensers, all designed to monitor medication usage, enhance adherence, and enable real-time communication between patients and healthcare providers. The rising incidence of chronic conditions, including asthma, diabetes, and cardiovascular diseases, is fueling demand for these advanced drug delivery systems. Poor medication adherence is a persistent issue in healthcare, leading to higher costs and suboptimal patient outcomes. Connected drug delivery devices help address these concerns by ensuring proper medication intake, streamlining disease management, and reducing hospital visits.

The market is segmented based on device type into connected sensors and integrated devices. Integrated devices accounted for the largest revenue share of 60.9% in 2024. These devices, equipped with reminders, tracking features, and real-time data-sharing capabilities, significantly improve patient compliance with treatment plans. The ability to monitor medication intake remotely has strengthened their adoption across healthcare settings. The increasing prevalence of chronic illnesses has further amplified the demand for integrated drug delivery solutions.

Based on technology, the market is divided into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment held the highest revenue share of 47.7% in 2024. Low power consumption, affordability, and seamless integration with mobile health applications have driven the widespread adoption of Bluetooth-enabled drug delivery devices. These devices facilitate real-time data exchange between patients and healthcare providers, supporting remote monitoring and digital health platforms. With the rising incidence of chronic diseases, Bluetooth-enabled smart inhalers, insulin pens, and autoinjectors are witnessing increased demand. Additionally, growing investments by pharmaceutical and MedTech companies in Bluetooth-based biosensors and wearable injectors are strengthening market expansion.

By application, the market is categorized into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other uses. The respiratory segment generated the highest revenue of USD 221 million in 2024. The increasing burden of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders has amplified the need for connected drug delivery solutions. These devices not only improve treatment adherence but also support remote patient monitoring, strengthening the expansion of telehealth services.

The market is also segmented by end use into hospitals, clinics, home care settings, and others. The home care segment led with USD 198.5 million in revenue in 2024. The growing preference for home-based healthcare, driven by an aging population and the rising need for chronic disease management, has fueled demand for connected drug delivery systems. These devices enable self-administration and remote monitoring, allowing patients to manage their conditions more efficiently.

The U.S. connected drug delivery devices market is projected to grow significantly from USD 156 million in 2023 to USD 2.7 billion by 2034. The increasing adoption of telehealth services, particularly after the COVID-19 pandemic, has accelerated the deployment of connected devices for remote healthcare monitoring.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising patient awareness about adherence to prescribed therapies
    • 3.2.1.2 Rapidly moving healthcare IT infrastructure
    • 3.2.1.3 Soaring adoption of machine learning, and artificial intelligence
    • 3.2.1.4 Rising implementation of telehealth platform integrated with AR/VR technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Security concerns regarding patient data
    • 3.2.2.2 High price of devices
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Device Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Connected sensors
  • 5.2.1 Connected inhalation sensors
  • 5.2.2 Connected injectable sensors
• 5.3 Integrated devices
  • 5.3.1 Integrated inhalation devices
  • 5.3.2 Integrated injectable devices

Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Bluetooth
• 6.3 Near field communication
• 6.4 Wi-Fi

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Anaphylaxis
• 7.3 Respiratory
• 7.4 Cardiovascular
• 7.5 Diabetes
• 7.6 Hormone replacement
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Home care settings
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Switzerland
  • 9.3.8 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Thailand
  • 9.4.7 Indonesia
  • 9.4.8 Vietnam
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Columbia
  • 9.5.5 Peru
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Israel

Chapter 10 Company Profiles

• 10.1 Adherium
• 10.2 Aptar Pharma
• 10.3 AstraZeneca
• 10.4 Becton, Dickinson, and Company
• 10.5 Bigfoot Biomedical
• 10.6 Cohero Health
• 10.7 Eli Lilly and Company
• 10.8 Insulet Corporation
• 10.9 Novartis
• 10.10 Novo Nordisk
• 10.11 Phillips Medisize
• 10.12 Propeller Health
• 10.13 Teva Pharmaceuticals
• 10.14 West Pharmaceutical Services
• 10.15 Ypsomed